Global Drug Sector Faced with New Tariffs and Challenges
The international pharmaceutical industry is feeling the pressure as countries consider imposing new tariffs on drug exports amid escalating trade tensions. These policy changes are complicating supply chains worldwide, pushing operational costs to new heights.
Central to this evolving landscape is Merck & Company (MRK), a key player known for its strong dividend track record. With the patent for Keytruda, which generates about 40% of Merck’s pharmaceutical revenue, set to expire in 2028, the company needs to quickly explore its next growth avenues.
In light of these challenges, Merck has initiated a significant $3 billion cost-cutting strategy to better position itself against potential tariff impacts. The question remains—can Merck uphold its dividend reputation while navigating these tariff pressures and the impending patent expiration through a mix of cost management and innovation?
Merck boasts a market value of roughly $196.1 billion, underpinned by its oncology portfolio and the growth of its animal health division. Offering an annual dividend of $3.24 per share with an attractive yield of 4.15%—coupled with a disciplined payout ratio of 40.41%—Merck has established itself as a reliable choice for investors seeking income.
However, the stock has experienced a decline of 20.3% over the past year. Presently, it appears to be undervalued, exhibiting a positive price-to-earnings ratio of 8.75 times, a substantial sector discount of 48%, and a price-to-sales ratio of 3.03, which seems appealing.
The most recent quarterly revenue report, released on July 29, provided a clear picture of the hurdles Merck faces. The company reported total revenues of $15.8 billion, reflecting a slight 2% year-on-year drop. CEO Robert Davis noted that “performance was in line with our expectations,” emphasizing resilience in both its oncology and animal health divisions. The GAAP earnings per share (EPS) was $1.76, while the non-GAAP EPS stood at $2.13, factoring in a $0.07 fee linked to the termination of a licensing agreement with Hengrui Pharma.
Keytruda again demonstrated its importance, generating $8 billion in quarterly sales—a 9% increase from the prior year—which contributed nearly half of the company’s total drug revenue. This strong performance helped mitigate significant losses from Gardasil, which saw a 55% decline in sales due to a halt in Chinese freight amid waning demand, underscoring the vulnerability of global trade dynamics.
On a positive note, Winrevair, recently launched by Merck, brought in $336 million for the quarter, bringing its cumulative sales to $1 billion since its approval. Merck’s investment in its animal health sector is proving beneficial, with revenues up 11% to $1.6 billion.
The company is focused on optimizing its operations with a multi-year plan aimed at achieving $1.7 billion in annual savings by 2027. This initiative includes enhancing R&D efficiencies and overall management. As the expiration of Keytruda’s U.S. patent approaches, Merck’s proactive stance is increasingly crucial.
It’s clear that Merck is taking decisive steps, as evidenced by the $649 million spent on restructuring in the last quarter alone. The company is looking to fortify its position against sector challenges and possible market disruptions.
Moreover, Merck is not just focused on cost-cutting—there are growth ambitions as well. A planned $10 billion acquisition of Verona Pharma slated for July 2025 demonstrates a commitment to broadening its portfolio and innovating therapies, having already brought forward Ohtuvayre, the first new inhaled COPD treatment in over two decades.
Additionally, Merck is embracing digital transformation to boost its commercial capabilities. Collaborating with Veeva Systems, the company is enhancing its core technologies to ensure success for upcoming product launches.
Expectations for revenue in the third quarter indicate earnings of $2.41 per share, reflecting a 53.5% year-on-year growth. Management has adjusted annual revenue forecasts between $64.3 billion and $65.3 billion, with non-GAAP EPS projected between $8.87 and $8.97.
Market sentiment among analysts leans moderately positive, with 24 analysts rating MRK as a “medium buy.” The average price target suggests a notable increase of about 30.1% from current levels.
That said, not all voices on Wall Street share this enthusiasm. For instance, Cantor Fitzgerald has maintained a “neutral” rating, lowering its price target slightly.
In the coming weeks, investors should closely monitor Merck’s updates on its cost-saving strategies, the Verona acquisition, and the impending Keytruda patent expiration. Simply cutting costs will not solve all challenges; real progress hinges on successfully launching new products and smart strategic deals. If Merck can navigate these hurdles without unexpected tariff disruptions, there may be prospects for stock recovery, though volatility is likely to persist until clearer momentum emerges.
